WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Tuesday, March 19, 2019 
Add Press Release News | News Feeds Feeds | Email This News Email

M&A Activities in the Pharma Contract Manufacturing Industry, 2015-2017 - 130 Acquisitions of Service Providers, 2018 Report
Friday, January 11, 2019

DUBLIN, Jan. 11, 2019 /PRNewswire/ --

The "PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition" report has been added to's offering.

"PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition" analyzes merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry during the period 2015-2017. The services considered in this report are contract manufacturing of active pharmaceutical ingredients (APIs) and finished dose products, associated analytical services, and packaging. Contract research providers were excluded.

Mergers and Acquisitions of companies and facilities have been a high profile feature of the pharmaceutical CMO industry in current times. Acquisition deals consistently receive high profile coverage in industry news media, with questions surrounding valuations, strategic intent and which companies are potentially next targets continuously debated in the industry.

There were 130 acquisitions of service providers during the three-year period from 2015-2017. The majority of acquisitions targeted contract manufacturing organizations (CMOs) that focused on APIs-small molecule, dose, and analytical services. Nearly 70% of acquirers of services companies were strategic acquirers, that is, they were operating companies rather than investment firms. A few services companies changed hands as a consequence of the purchase of their parent company, while several CMOs were acquired by bio/pharma companies seeking to secure product supply.

More than half of acquirers were public companies, although 36% of company acquisitions were by PE firms or by CMOs owned by PE firms, with a high level of influence on the industry. Companies with complex technologies, including biologics manufacturing, are likely to be sought-after targets, as well as CMOs with specialized capabilities. However, in the coming years, M&A activity will be hindered by higher interest rates, uncertain trade and investment policies, high valuation expectations, and sizeable debt loads carried by some of the most active acquirers.


    --  Helps bio/pharmaceutical manufacturing, development, and supply chain
        executives understand the implications of M&A activity on their supply
        base and sourcing options.
    --  Helps executives at CMOs and associated contract services companies and
        investors to recognize the significance of M&A activities for the
        competitive dynamics of the industry and how company strategies must
        change to address the altering market.
    --  To gain insights that might enable predictions of the nature and
        implications of M&A activity in the next three to five years.

Reasons to Buy

    --  CMOs: market trends, strategic planning, competitive intelligence,
        performance benchmarking
    --  Bio/Pharma: supplier performance benchmarking, market trends,
        competitive intelligence
    --  Private equity and Stock analysts: target identification and analysis,
        portfolio company performance benchmarking.

Key Topics Covered:

1. Executive Summary

2 Objectives and Methodology

3 Overview of M&A Activity 2015-2017
Target Characteristics
Acquirer Characteristics

4 Segment Close-Ups of M&A Activity, 2015-2017
Dose Manufacturing
API - Biologic
API - Small Molecule
Analytical Services
Formulation and Clinical Supplies Manufacturing

5 Valuations

6 Facility Acquisitions

7 What It Means

8 The Outlook for M&A in the Manufacturing Services Industry

9 Notes on Methodology

10 Appendix
Service Acquisitions 2015-2017
Primary Research - Key Opinion Leaders Cited in this Report

Companies Mentioned

    --  3SBio
    --  ABC Laboratories
    --  Absorption Systems
    --  Abzena
    --  Acacia Lifesciences
    --  Accucaps
    --  Accuratus Lab Services
    --  Advanced BioScience Laboratories
    --  Advantar Laboratories
    --  Aeras
    --  Agere Pharmaceuticals
    --  AGIC Capital
    --  Ajinomoto
    --  Akorn

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav The Best Types Of Marketing Videos In 2019 - Plus, The Top 26 Video Marketing Agencies, According To DesignRush | Mar 19, 2019
Nav Polystar's Kalix Helps Asia Pacific Operator Optimise Services and Integrate Data with Key Systems, Boosting Visibility for High-profile Sporting Events and Roaming | Mar 19, 2019
Nav The Fourth Type of Chocolate Introduces a Crowdsourced Platform for Consumers | Mar 19, 2019
Nav Intouch Solutions Accelerates Growth With Boston Office Opening and Hire of Senior Vice President | Mar 19, 2019
Nav SPA Sigma & Strategic Pricing Associates Doug Wyatt wins Sales Operations & Enablement Award | Mar 19, 2019
Nav New San Antonio Digital Marketing Agency Focuses on Local Business Growth, Contributing to Economy Boost | Mar 19, 2019
Nav Digital Marketing Company, fishbat, Shares 6 Ways Small Businesses Can Maximize the Impact of YouTube Marketing | Mar 19, 2019
Nav V Digital Services Ranks High in Ranking Arizona | Mar 19, 2019
Nav Sony Electronics Taps Senior Leadership to Drive Imaging and Professional Solutions Business Strategy | Mar 19, 2019
Nav IntelePeer's Atmosphere┬« CPaaS Drives Increased Customer Engagement and Revenue for Unimed Brand, Chamonix | Mar 19, 2019

Submit News | View More News View More News